Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 73

The DOI matches its Crossref record.

A Placebo-Controlled Comparison of the Efficiency of Triple- and Monotherapy in Category III B Chronic Pelvic Pain Syndrome (CPPS)

Tuğcu, Volkan, Taşçı, Ali İhsan, Fazlıoğlu, Adem, Gürbüz, Gökhan, Özbek, Emin, Şahin, Selçuk, Kurtuluş, Fatih, Çek, Mete · 2007 · European Urology

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2006.09.036

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

No references could be resolved yet.

Research works printed but not linked: 23

  1. McNaughton-Collins, 1998, How common is prostatitis? A national survey of physician visits, J Urol, 159, 1224, 10.1016/S0022-5347(01)63564-X · DOI · Paper page
  2. Wenninger, 1996, Sickness impact of chronic nonbacterial prostatitis and its correlates, J Urol, 155, 965, 10.1016/S0022-5347(01)66359-6 · DOI · Paper page
  3. Calhoun, 2004, The economic impact of chronic prostatitis, Arch Intern Med, 164, 1231, 10.1001/archinte.164.11.1231 · DOI
  4. Krieger, 1999, NIH consensus definition and classification of prostatitis, JAMA, 282, 236, 10.1001/jama.282.3.236 · DOI · Paper page
  5. Nickel, 1999, Prostatitis: Evolving management strategies, Urol Clin North Am, 26, 737, 10.1016/S0094-0143(05)70215-9 · doi:10.1016/s0094-0143(05)70215-9
  6. Meares, 1968, Bacteriologic localization patterns in bacterial prostatitis and urethritis, Invest Urol, 5, 492
  7. Hellstrom, 1987, Neuromuscular dysfunction in nonbacterial prostatitis, Urology, 30, 183, 10.1016/0090-4295(87)90193-2 · doi:10.1016/0090-4295(87)90193-2
  8. Barbalias, 1983, Prostatodynia: clinical and urodynamic characteristics, J Urol, 130, 514, 10.1016/S0022-5347(17)51281-1 · doi:10.1016/s0022-5347(17)51281-1
  9. Kirby, 1982, Intra-prostatic urinary reflux: an aetiological factor in abacterial prostatitis, BJU Int, 54, 729, 10.1111/j.1464-410X.1982.tb13635.x · doi:10.1111/j.1464-410x.1982.tb13635.x
  10. Roehrborn, 2001, Alfuzosin: Overview of pharmacokinetics, safety, and efficacy of a clinically uroselective α-blocker, Urology, 58, 55, 10.1016/S0090-4295(01)01322-X · doi:10.1016/s0090-4295(01)01322-x
  11. Osborn, 1981, Prostatodynia—physiological characteristics and rational management with muscle relaxant, Br J Urol, 156, 621, 10.1111/j.1464-410X.1981.tb03275.x · DOI
  12. De La Rosette, 1992, Research in ‘prostatitis syndromes’: The use of alfuzosin (a new alfa 1 receptor blocking agent) in patients mainly presenting with micturition complaints of an irritative nature and confirmed urodynamic abnormalities, Eur Urol, 22, 222, 10.1159/000474760 · doi:10.1159/000474760
  13. Cheah, 2003, Terazosin therapy for chronic prostatitis/chronic pelvic pain syndrome: A randomized, placebo controlled trial, J Urol, 169, 592, 10.1016/S0022-5347(05)63960-2 · doi:10.1016/s0022-5347(05)63960-2
  14. Cheah, 2004, Initial, long term, and durable responses to terazosin, placebo, or other therapies for chronic prostatitis/chronic pelvic pain syndrome, Urology, 64, 881, 10.1016/j.urology.2004.06.041 · DOI · Paper page
  15. Evliyaoglu, 2002, Lower urinary tract symptoms, pain and quality of life assessment in chronic non-bacterial prostatitis patients treated with α-blocking agent doxazosin; versus placebo, Int Urol Nephrol, 34, 351, 10.1023/A:1024487604631 · DOI · Paper page
  16. Mehik, 2003, Alfuzosin treatment for chronic prostatitis/chronic pelvic pain syndrome: A prospective, randomized, double-blind, placebo-controlled, pilot study, Urology, 62, 425, 10.1016/S0090-4295(03)00466-7 · DOI · Paper page
  17. Alexander, 2004, Ciprofloxacin or tamsulosin in men with chronic prostatitis/chronic pelvic pain syndrome: A randomized, double blind trial, Ann Intern Med, 141, 581, 10.7326/0003-4819-141-8-200410190-00005 · DOI · Paper page
  18. Nickel, 2004, Treatment of chronic prostatitis/chronic pelvic pain syndrome with tamsulosin: a randomized double blind trial, J Urol, 171, 1594, 10.1097/01.ju.0000117811.40279.19 · DOI
  19. Dinis, 2005, The distribution of sensory fibers immunoreactive for the TRPV1 (capsaicin) receptor in the human prostate, Eur Urol, 48, 162, 10.1016/j.eururo.2005.01.009 · DOI
  20. Canale, 1993, Use of a novel non-steroid anti-inflammatory drug, nimesulide, in the treatment of abacterial prostato-vesiculitis, Andrologia, 25, 163, 10.1111/j.1439-0272.1993.tb02701.x · doi:10.1111/j.1439-0272.1993.tb02701.x
  21. Nickel, 2001, Effects of rofecoxib in patients with chronic nonbacterial prostatitis: a placebo controlled pilot study, J Urol, 165, 27
  22. Shoskes, 2003, Long-term results of multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome, J Urol, 169, 1406, 10.1097/01.ju.0000055549.95490.3c · DOI
  23. Cornel, 2005, The effect of biofeedback physical therapy in men with chronic pelvic pain syndrome type III, Eur Urol, 47, 607, 10.1016/j.eururo.2004.12.014 · DOI · Paper page

Cited by

See all 73

Metadata

Authors
Tuğcu, V., Taşçı, A. İ., Fazlıoğlu, A., Gürbüz, G., Özbek, E., Şahin, S., Kurtuluş, F., & Çek, M.
Venue
European Urology
Publisher
Elsevier BV
Published
2007-04
Volume
51
Issue
4
Pages
1113-1118
ISSN
0302-2838
Cited by
73
References
0
Language
en
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Placebo-Controlled Comparison of the Efficiency of Triple- and Monotherapy in Category III B Chronic Pelvic Pain Syndrome (CPPS). https://app.cochat.ai/papers/10.1016/j.eururo.2006.09.036
The paper
Tuğcu, V., Taşçı, A. İ., Fazlıoğlu, A., Gürbüz, G., Özbek, E., Şahin, S., Kurtuluş, F., & Çek, M. (2007). A Placebo-Controlled Comparison of the Efficiency of Triple- and Monotherapy in Category III B Chronic Pelvic Pain Syndrome (CPPS). European Urology. https://doi.org/10.1016/j.eururo.2006.09.036

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.